The two-phase free boundary problem for the Navier-Stokes system is considered in a situation where the initial interface is close to a halfplane. By means of L p -maximal regularity of the underlying linear problem we show local well-posedness of the problem, and prove that the solution, in particular the interface, becomes instantaneously real analytic.
A phase II pilot study of bendamustine as salvage treatment in patients with advanced breast cancer was performed to determine the objective response rates and make further observations on the toxicity of this drug. A group of 37 patients, pretreated with chemotherapy for advanced disease, entered the trial. Treatment consisted of 150 mg/m2 bendamustine on days 1 and 2 of a 4-week treatment course. Patients continued to receive treatment until complete remission and then two further courses, until tumour progression or unacceptable toxicity ensued. A total of 36 patients received at least one treatment course and were assessable for toxicity; 33 patients were evaluable for treatment results. Dose-limiting grade 3 and 4 WHO toxicity occurred in 5 and 3 patients respectively; 27% of patients entered complete or partial tumour remission. The median time to tumour progression was 2 months with a range of 1-14 months. The efficacy of bendamustine was apparently independent of pretreatment with anthracyclines, suggesting a lack of cross-resistance between bendamustine and anthracyclines. It can be concluded that bendamustine in the dose and application schedule used here is active in the salvage therapy of women with advanced breast cancer. The toxicity was acceptable. Future studies have to confirm the data of this pilot trial and to define the role of bendamustine in the combination chemotherapy of metastatic breast cancer that has been suggested by previous trials.
Abstract. We study the generation of an analytic semigroup in L p (R d ) and the determination of the domain for a class of second order elliptic operators with unbounded coefficients in R d . We also establish the maximal regularity of type L q -L p for the corresponding inhomogeneous parabolic equation. In contrast to the previous literature the coefficients of the second derivatives are not required to be strictly elliptic or bounded. Interior singularities of the lower order terms are also discussed.
Most problems in applications are inverse source problems or identification problems. This review deals with a systematic treatment of the nonnegative sources (measures) relative to the Laplace equation and the heat conduction equation producing the same potential outside a domain • C R 3. This set is convex and weakly compact. Therefore the basic theorems on convex sets can be applied to such problems. Sets of extremal measures are characterized by geometric conditions. Almost nothing is known about the structure of the sources which produce the earth's gravitational field. Therefore these investigations may be of interest for the inverse problem in gravimetry. The following question remains unanswered in this review: to find additional conditions to select uniquely a measure producing the earth's gravitational field. This question is unanswered in most inverse source problems.
Background: In an open pilot study we tested a program of reduced combined radio-chemotherapy in Hodgkin’s disease in limited stages with risk factors and in advanced stages. Aim of the study was to reduce the delayed complications of full-dose combined modality treatment while preserving its effectiveness. Material and Methods: From May 1985 to December 1988 43 previously untreated consecutive patients entered the study. Treatment consisted of CVPP/ABVCy hybrid chemotherapy and low-dose (25 Gy) involved-field radiotherapy. Results: All patients could be evaluated for response to treatment. Primary complete remission (CR) reached 35/43, partial remission 5/43 (12%), and 3/43 (7%) did not respond. After a median observation period of 64 months 28/35 (80%) are in first CR. The survival data are as follows: relapse-free survival 3 years 86%, 5 years 78%, overall survival 3 years 91%, 5 years 83% (Kaplan-Meier estimation). So far 7 patients relapsed and 7 patients died. The acute toxicity of the treatment program was acceptable and up to now we have not observed secondary neoplasms. Conclusions: We regard our treatment approach as useful; it matches the reports of other groups using similar treatment policies.
The study of the basic model for incompressible two-phase flows with phase transitions in the case of equal densities, initiated in the paper Prüss, Shibata, Shimizu, and Simonett [16], is continued here with a stability analysis of equilibria and results on asymptotic behaviour of global solutions. The results parallel those for the thermodynamically consistent Stefan problem with surface tension obtained in Prüss, Simonett, and Zacher [19].
Mathematics Subject Classification (2010):Primary: 35R35, 35K55, 35B35, Secondary: 35Q30, 76D45, 80A22.
We report on two patients with chemoresistant B-cell chronic lymphocytic leukemia who were treated successfully with the monoclonal anti-CD 20 antibody rituximab. Both patients suffered from severe thrombocytopenia requiring platelet transfusions over a period of several months. Neither chemotherapy nor immunosuppressive agents (corticoids, immunoglobulins) were effective. After four doses of rituximab (375 mg/m2 weekly), both patients recovered within a few weeks to hematological partial remission. One patient was re-treated successfully three times after relapses. Both patients were premedicated with prednisone (100 mg) 30 min prior to the infusion to prevent cytokine release and the antibody infusions were well tolerated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.